Related Experiment Video
Updated: Jun 14, 2026

A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation
Published on: March 15, 2018
Lovastatin induces VSMC differentiation through inhibition of Rheb and mTOR
Robert J Wagner1, Kathleen A Martin, Richard J Powell
1Section of Vascular Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, USA.
Abstract:
It is becoming increasingly clear that cholesterol-independent effects of statins also contribute to the cardioprotective effects, but these mechanisms remain poorly understood. We investigated the effects of lovastatin on vascular smooth muscle phenotype. We have previously shown that mammalian target of rapamycin complex 1 (mTORC1) inhibition with rapamycin induces vascular smooth muscle cell (VSMC) differentiation. We found that lovastatin also inhibits mTORC1 signaling and that this inhibition is required for VSMC differentiation. Lovastatin inhibition of mTORC1 was farnesylation dependent, suggesting the farnesylated G protein Rheb (Ras homologue enriched in brain), a known upstream activator of mTORC1. Rheb overexpression induced mTORC1 activity and repressed contractile protein expression, but a farnesylation-deficient mutant (C18S) elicited the opposite effect. Rheb knockdown with small interfering RNA was also sufficient to inhibit mTORC1 and induce contractile protein expression, and it prevented statin-induced VSMC differentiation. Notably, mTORC1 activity was elevated in VSMC isolated from an intimal hyperplastic patient lesion compared with normal media, and lovastatin treatment inhibited mTORC1 activity in these cultures. Furthermore, lovastatin inhibited mTORC1 activity and prevented the downregulation of contractile protein expression in an ex vivo angioplasty model. In conclusion, these findings illustrate a mechanism for the cardioprotective effects of lovastatin through inhibition of Rheb and mTORC1 and promotion of a differentiated VSMC phenotype.
Insights
Lovastatin promotes cardiovascular health by inhibiting Rheb and mTORC1 signaling, leading to vascular smooth muscle cell (VSMC) differentiation. This mechanism enhances the cardioprotective effects of statins beyond cholesterol reduction.
Area of Science:
- Cardiovascular Biology
- Molecular Pharmacology
- Cellular Signaling
Background:
- Cholesterol-independent effects of statins contribute to cardioprotection, but mechanisms are unclear.
- Mammalian target of rapamycin complex 1 (mTORC1) inhibition induces vascular smooth muscle cell (VSMC) differentiation.
- Statins' effects on VSMC phenotype warrant investigation.
Purpose of the Study:
- To investigate the effects of lovastatin on vascular smooth muscle cell (VSMC) phenotype.
- To elucidate the role of mammalian target of rapamycin complex 1 (mTORC1) signaling in lovastatin-induced VSMC differentiation.
- To identify upstream regulators of mTORC1 involved in lovastatin's actions.
Main Methods:
- Investigated lovastatin's impact on VSMC phenotype and mTORC1 signaling.
- Utilized Rheb overexpression and knockdown (small interfering RNA) to assess its role in mTORC1 regulation.
- Examined mTORC1 activity and contractile protein expression in patient-derived cells and an ex vivo angioplasty model.
Main Results:
- Lovastatin inhibits mTORC1 signaling, which is essential for VSMC differentiation.
- Lovastatin's mTORC1 inhibition is dependent on farnesylation, implicating the G protein Rheb.
- Rheb activity inversely correlates with contractile protein expression; Rheb knockdown mimics lovastatin's effects.
- Elevated mTORC1 activity in intimal hyperplasia lesions was reduced by lovastatin treatment.
- Lovastatin inhibited mTORC1 and preserved contractile proteins in an ex vivo angioplasty model.
Conclusions:
- Lovastatin promotes a differentiated VSMC phenotype through Rheb and mTORC1 inhibition.
- This mechanism contributes to the cardioprotective effects of statins, independent of cholesterol.
- Targeting Rheb-mTORC1 signaling offers a potential therapeutic strategy for vascular diseases.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Cholesterol: Significance and Regulation
Considering cholesterol and...
TGF - β Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
